Francois-Clement Bidard

Professor of Medical Oncology

Institut Curie
Country flagFrance
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (27)

Purpose: In patients with metastatic breast cancer, ≥5 circulating tumor cells (CTC)/7.5 mL of blood is a validated adverse prognostic marker. The STIC CTC phase III trial ( N = 778, hormone receptor–positive HER2− metastatic breast cancer) showed that ≥5 CTC/7.5 mL before treatment predicted greater benefit from first-line chemotherapy over endocrine therapy for progression-free (PFS) and overall survival (OS). This exploratory analysis examines these results by histologic subtype, comparing invasive lobular carcinoma (ILC) and carcinoma of no special type (NST). Experimental Design: Baseline CTC count (CellSearch) and its impact on PFS and OS were compared between ILC ( N = 159) and NST ( N = 571). The survival benefit of chemotherapy in patients with a high CTC count was then re-evaluated separately for each subtype. Results: Before treatment, ILC had significantly higher CTC counts than NST [median, 10 (Q1 = 2, Q3 = 40) vs. 1 (Q1 = 0, Q3 = 7)]. ≥5 CTC/7.5 mL were detected in 64% (95% confidence interval, 56–71) of patients with ILC and 31% (95% confidence interval, 28–35) of patients with NST, correlating with shorter PFS and OS in both. However, patients with ILC and ≥5 CTC/7.5 mL saw no significant benefit from CTC-informed chemotherapy [PFS: HR, 0.91 (0.55–1.52); OS: HR, 0.83 (0.46–1.52)]. In contrast, patients with NST and ≥5 CTC/7.5 mL had markedly improved outcomes with chemotherapy [PFS: HR, 0.54 (0.37–0.81); OS: HR, 0.37 (0.21–0.66)]. Conclusions: ILC sheds more CTC than NST, likely owing to underlying biological differences. Although the ≥5 CTC/7.5-mL threshold remained a valid prognostic marker for both, it was predictive of chemotherapy benefit in NST but not in ILC. These findings highlight differences in biomarker utility between ILC and NST, affecting both threshold relevance and treatment response.

Year:

2025

Supplementary Table 9. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients that received chemotherapy-based or endocrine therapy-based treatment.

Year:

2025

Supplementary Table 3: Comparisons of the probabilities of being CTC positive among tumor subtypes (hormone receptor-positive/HER2-negative, HER2-positive, triple-negative) according to time point of CTC assessment (baseline, first follow-up) and cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being CTC positive are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC positive (yes vs no)

Year:

2025

Supplementary Table 7. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients with hormone receptor-positive/HER2-negative, HER2-positive and triple-negative tumors.

Year:

2025

Supplementary Table 4: Comparisons of the probabilities of being CTC positive betweenHER2- positive/hormone receptor-positive and HER2-positive/hormone receptor-negative tumors according to time point of CTC assessment (baseline, first follow-up) and cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being CTC positive are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC positive (yes vs no).

Year:

2025

Supplementary Figure 4. Kaplan-Meier plot of overall survival according to change in CTC status from baseline to first follow-up (cutoff for CTC positivity ≥1 CTC). (A) HER2-positive/hormone receptor-positive tumors; (B) HER2-positive/hormone receptor-negative tumors. Survival time is given as time since baseline CTC assessment in months. The P-values refers to the global log rank test with 3 degrees of freedom.

Year:

2025

Supplementary Figure 3: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for HER2-positive/hormone receptor-positive tumors(A, B) and HER2-positive/hormone receptor-negative tumors(C, D). Survival time is given as time since baseline CTC assessment in months. (A, C) cutoff for CTC positivity ≥1 CTC; (B, D) cutoff for CTC positivity ≥5 CTCs. The P-values refer to pairwise comparisons with the log rank test.

Year:

2025

Supplementary Figure 2: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for a cutoff for CTC positivity ≥1 CTC (A, B, C) and a cutoff for CTC positivity ≥5 CTCs (D, E, F). Survival time is given as time since baseline CTC assessment in months. (A, D) hormone receptor-positive/HER2-negative tumors; (B, E) HER2- positive tumors; (C, F) triple-negative tumors. The P-values refer to pairwise comparisons with the log rank test.

Year:

2025

Supplementary Table 2. Absolute and relative frequencies of CTC change groups and percentage of CTC responders (as categorized according to the ≥1 CTC or ≥5 CTC cutoff for CTC positivity) overall, according to tumor subtypes and according to treatment type.

Year:

2025

Supplementary Table 5: Comparisons of the probabilities of patients that are CTC positive at baseline being a CTC responder (i.e., switching from CTC positive at baseline to CTC negative at first follow-up) among tumor subtypes (hormone receptor-positive/HER2-negative, HER2-positive, triple-negative) according to cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being a CTC responder are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC responder (yes vs no).

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (54)

Anne Vincent‐Salomon

Professor (associate)

Université Paris Dauphine-PSL

FRANCE
View details

Charlotte Proudhon

INSERM scientist, Group leader - Team Circulating EpiMarkers

-

FRANCE
View details

Etienne BRAIN

Institut Curie

FRANCE
View details

Emanuela Romano

PSL Research University

FRANCE
View details

Olivier Lantz

Institut Curie

FRANCE
View details

Ivan Bieche

Université Paris Cité

FRANCE
View details

Alice Chen

Head, Early Clinical Trial Development Program

National Cancer Institute

UNITED STATES
View details

Elisabeth de Vries

Scientific Staff

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Joyce O'Shaughnessy

Baylor University Medical Center

UNITED STATES
View details

Catherine Alix-Panabières

Director/Professor

University Hospital of Montpellier

FRANCE
View details

Paola Gazzaniga

Sapienza University of Rome

ITALY
View details

Patrick Neven

University Hospitals Leuven

BELGIUM
View details

Daniel F. Hayes

Stuart B. Padnos Professor of Breast Cancer Research

University of Michigan Rogel Cancer Center

UNITED STATES
View details

Michail Ignatiadis

Leader Investigator Initiated Trials

Institut Jules Bordet

BELGIUM
View details

Alexander W. Wyatt

Assistant Professor

The University of British Columbia

CANADA
View details

Chloé-Agathe Azencott

Professor

Mines ParisTech

FRANCE
View details

Lisa Anne Carey

Deputy Director for Clinical Science

University of North Carolina at Chapel Hill

UNITED STATES
View details

Scott A. Laurie

University of Ottawa

CANADA
View details

Lars Dyrskjøt

Aarhus University Hospital

DENMARK
View details

Christophe Le Tourneau

Head of Early Phase Clinical Trials

Institut Curie

FRANCE
View details

Nadia Harbeck

-

GERMANY
View details

Hope Rugo

Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology

City Of Hope National Medical Center

UNITED STATES
View details

Jean-Yves Pierga

Head of Department

Institut Curie

FRANCE
View details

Karthik Giridhar

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Anne Tardivon

PSL Research University

FRANCE
View details

Kelly K Hunt

Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Tanja Fehm

Professor

University Hospital Düsseldorf

GERMANY
View details

Carlos Caldas

Professor

Hebrew University of Jerusalem

ISRAEL
View details

Peter Schmid

Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine

Barts Cancer Institute

UNITED KINGDOM
View details

Leon W. M. M. Terstappen

University of Twente

NETHERLANDS
View details

Luis Teixeira

Université Paris Cité

FRANCE
View details

Peter Fasching

-

GERMANY
View details

Swati Kulkarni

Professor of Surgery

Northwestern University

UNITED STATES
View details

Véronique Dieras

Head Breast Group

-

FRANCE
View details

Elena Garralda

Director

-

SPAIN
View details

Elisabetta Munzone

Director

European Institute of Oncology

ITALY
View details

Justin Stebbing

Professor

Imperial College London

UNITED KINGDOM
View details

Evi Lianidou

PROFESSOR

National and Kapodistrian University of Athens

GREECE
View details

Hervé J. BRISSE

Head of Imaging Departement

Université PSL

FRANCE
View details

Minetta Liu

Research Collaborator, Professor

Mayo Clinic

UNITED STATES
View details

Anthony Gonçalves

Aix-Marseille University

FRANCE
View details

Virginia Kaklamani

Professor

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Aditya Bardia

UCLA Health

UNITED STATES
View details

Maud Kamal

Institut Gustave Roussy

FRANCE
View details

Massimo Cristofanilli

Professor of Medicine

Weill Cornell Medicine

UNITED STATES
View details

Miguel Martin

Universidad Complutense de Madrid

SPAIN
View details

Klaus Pantel

-

GERMANY
View details

Manali Bhave

Assistant Professor

Winship Cancer Institute of Emory University

UNITED STATES
View details

Eva M. Ciruelos-Gil

Universidad Complutense de Madrid

SPAIN
View details

Caroline Malhaire

Institut Curie

FRANCE
View details

Markus Wallwiener

University Hospital Heidelberg

GERMANY
View details

DANIELE GENERALI

University of Trieste

ITALY
View details

Rodrigo Toledo

Miguel Servet Researcher (Assistant Professor)

Vall d'Hebron Institute of Oncology

SPAIN
View details

Kostandinos Sideras

Assistant Professor

Mayo Clinic

UNITED STATES
View details